Nabsys
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $2.8m | Seed | |
$4.0m | Series A | ||
$7.0m | Series B | ||
$10.0m | Series C | ||
$35.0m | Series D | ||
N/A | $25.5m | Series E | |
| $21.0m Valuation: $128m | Series F | |
* |
| $25.0m Valuation: $128m | Late VC |
* | $13.0m Valuation: $128m | Late VC | |
* | N/A | Acquisition | |
Total Funding | €130m |
Related Content
Recent News about Nabsys
EditNabsys is a pioneering company in the field of genomic analysis, specializing in semiconductor-based tools that enable the examination of entire genomes in very large fragments. Operating primarily in the biotechnology and genomics markets, Nabsys serves research institutions, clinical laboratories, and pharmaceutical companies. The company's core product is its high-definition mapping instrument, which includes an electronic nanodetector chip, pre-loaded application protocols, analytical software, and all necessary reagents for comprehensive genomic analysis. Nabsys generates revenue through the sale of these instruments and associated consumables, as well as through service contracts for ongoing support and software updates. The business model focuses on providing cost-effective, accurate, and comprehensive genomic structural information, making advanced genomic research accessible to a broader range of laboratories.
Keywords: Genomic analysis, semiconductor tools, high-definition mapping, electronic nanodetector, biotechnology, research institutions, clinical laboratories, pharmaceutical companies, cost-effective, comprehensive analysis.